经皮穿刺微波凝固联合替吉奥治疗结肠癌肝转移的疗效观察
Combined Percutaneous Microwave Coagulation Therapy and S-1 in Treatment of Liver Metastases from Colon Cancer
-
摘要: 目的 观察经皮穿刺微波凝固治疗(PMCT)术后联合替吉奥胶囊(S-1)治疗结肠癌肝转移的疗效。方法选择本中心2009年5月—2011年1月收治的56例结肠癌肝转移患者,分为PMCT术后联合替吉奥组(实验组,n=28)和单用PMCT组(对照组,n=28)。实验组PMCT术后口服替吉奥胶囊每日50 mg/m2,连续给药14天,停药7天,共化疗6个疗程。结果实验组和对照组治疗结束时完全缓解率分别为67.85%(19/28)和35.71%(10/28),部分缓解率分别为25%(7/28)和21.42%(6/28),稳定率分别为3.5%(1/28)和28.57%(8/28),有效率分别为92.85%(26/28)和57.14%(16/28),两组相比差异均有统计学意义(P<0.05)。不良反应主要为骨髓抑制、胃肠道反应等。结论结肠癌肝转移患者PMCT术后联合替吉奥化疗可提高患者术后生存率且不良反应较轻,是结肠癌根治术后伴肝转移有益的辅助治疗方案。Abstract: Objective To evaluate the effect of percutaneous microwave coagulation therapy (PMCT) combined with S-1 in the treatment of liver metastases from colon cancer. Methods From May 2009 to January 2011,56 patients with liver metastases from colon cancer were randomly divided into treatment group (PMCT and S-1) and control group (only PMCT).In the treatment group,S-1 was administered 50 mg/m2/d for 14 consecutive days following a 1-week rest,3 weeks for a cycle.The effects were evaluated after 6 cycles. Results There were 19 (67.85％) CR,7(25％) PR,1 (3.5％) SD in the treatment group,and 10(35.71％) CR,6(21.42％) PR,8 (28.57％) SD in the control group.The overall response rates were 92.85% and 57.14%,respectively.There was significant difference between two groups (P<0.05).Major adverse reactions were myelosuppressive and gastrointestinal toxicities. Conclusion PMCT combined with S-1 shows well tolerance and good effect as a new therapy for patients with liver metastases from colon cancer.
下载:
